The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAs major banking institutions re-evaluate their outlooks for key European sectors, Goldman Sachs has updated its coverage for Sanofi and Ryanair. According to reports, the bank lowered Sanofi's price target from EUR 89 to EUR 84 while maintaining a Neutral rating, reflecting a cautious stance on the French pharmaceutical giant. Conversely, the bank kept its Neutral rating on Ryanair but nudged the price target up from EUR 27 to EUR 28, signaling slight adjustments in performance expectations.
These revisions come as the healthcare sector faces competitive pressures while aviation attempts to navigate seasonal demand fluctuations; Sanofi's previous quarterly results showed a 6.4% growth in specialty medicine sales according to earnings reports, while Ryanair reported an 11% increase in passenger traffic this past May. Compared to peers, AstraZeneca trades at slightly higher earnings multiples, supporting Goldman's neutral stance on Sanofi per market data.
Investors should monitor current price levels, as Sanofi (SAN.PA) closed at EUR 77.03 as of July 6, 2026, while Ryanair (RYAAY) stood at USD 65.49 at the close of July 2, 2026. Looking ahead, market sentiment in the Eurozone may be influenced by recent inflation data from Germany and France, which showed annual CPI slowing to 2.3% and 1.8% respectively, potentially impacting consumer-facing sectors.